Engineering a Low-Immunogenic Mirror-Image VHH against Vascular Endothelial Growth Factor

Immunogenicity is a major caveat of protein therapeutics. In particular, the long-term administration of protein therapeutic agents leads to the generation of antidrug antibodies (ADAs), which reduce drug efficacy while eliciting adverse events. One promising solution to this issue is the use of mir...

Full description

Saved in:
Bibliographic Details
Published in:ACS chemical biology 2024-05, Vol.19 (5), p.1194-1205
Main Authors: Aoki, Keisuke, Higashi, Katsuaki, Oda, Sakiho, Manabe, Asako, Maeda, Kayuu, Morise, Jyoji, Oka, Shogo, Inuki, Shinsuke, Ohno, Hiroaki, Oishi, Shinya, Nonaka, Motohiro
Format: Article
Language:English
Subjects:
Animals
Humans
Immunoglobulin Heavy Chains - chemistry
Immunoglobulin Heavy Chains - immunology
Mice
Peptide Library
Protein Engineering - methods
Vascular Endothelial Growth Factor A - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunogenicity is a major caveat of protein therapeutics. In particular, the long-term administration of protein therapeutic agents leads to the generation of antidrug antibodies (ADAs), which reduce drug efficacy while eliciting adverse events. One promising solution to this issue is the use of mirror-image proteins consisting of d-amino acids, which are resistant to proteolytic degradation in immune cells. We have recently reported the chemical synthesis of the enantiomeric form of the variable domain of the antibody heavy chain (d-VHH). However, identifying mirror-image antibodies capable of binding to natural ligands remains challenging. In this study, we developed a novel screening platform to identify a d-VHH specific for vascular endothelial growth factor A (VEGF-A). We performed mirror-image screening of two newly constructed synthetic VHH libraries displayed on T7 phage and identified VHH sequences that effectively bound to the mirror-image VEGF-A target (d-VEGF-A). We subsequently synthesized a d-VHH candidate that preferentially bound the native VEGF-A (l-VEGF-A) with submicromolar affinity. Furthermore, immunization studies in mice demonstrated that this d-VHH elicited no ADAs, unlike its corresponding l-VHH. Our findings highlight the utility of this novel d-VHH screening platform in the development of protein therapeutics exhibiting both reduced immunogenicity and improved efficacy.
ISSN:1554-8929
1554-8937
DOI:10.1021/acschembio.4c00197